Homemarket Newsstocks News

    Biocon sells up to 5.1% stake in Syngene to fund Viatris biologics biz acquisition

    Biocon sells up to 5.1% stake in Syngene to fund Viatris biologics biz acquisition

    Biocon sells up to 5.1% stake in Syngene to fund Viatris biologics biz acquisition
    Read Time
    2 Min(s) Read
    Profile image

    By CNBCTV18.com  IST (Updated)

    Mini

    Indian biopharmaceutical company Biocon has sold upto 5.1 percent stake in the company for a price band of Rs 550 to Rs 573. 

    Biocon has sold up to 5.1 percent stake in Syngene International for a price band of Rs 550 to Rs 573 to fund the equity component of the $3.3 billion acquisition of biologics business from Viatris.
    The shares of contract research and manufacturing firm Syngene International climbed 3.5 percent in early trade on Tuesday, September 6, after 2.3 crore shares of the company, worth 5.7 percent equity, changed hands for Rs 564 per share.
    Biocon stock opened 0.8 percent higher and subsequently fell 0.3 percent on Tuesday.
    On Monday, CNBC-TV18 reported that Indian biopharmaceutical company Biocon was likely to sell a portion of its 69.99 percent stake in Syngene International.
    Biocon has said that the company is on track to close the Viatris deal signed in 2022. As per the deal, for closing Biocon Biologics will pay $2 billion to Viatris. Of these 2 billion, the company will receive $50 million from Viatris for capex, and $1.8 billion have been received from debt commitment. $335 million will be deferred payment that the company will pay mainly via internal cash generation.
    The remaining $800 million will be generated via equity commitment — this $800m equity component is the reason Biocon is selling stake in Syngene.
    $550 million will be from old and new PE investors including Serum that is looking to raise stake in Biocon Biologics.
    Biocon will explore fundraising options such as selling stake in Syngene to raise the needed remaining $250 million.
    Apart from Biocon promoters, Biocon Limited Employee Welfare Trust holds 0.29 percent stake in Syngene International, taking the total stake to about 70.29 percent.
    Of the 12 analysts tracking Syngene, 75 percent give a 'buy' rating while another eight percent have given a 'hold' on the shares of the company. 17 percent have a 'sell' recommendation.
    Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
    arrow down

      Most Read

      Market Movers

      View All
      CompanyPriceChng%Chng